

THE AMERICAN JOURNAL OF MANAGED CARE®

November 2013 – Vol. 19, No. 13, Sup.

Publishing Staff

Senior Vice President
of Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Clinical Projects Managers

Ida Delmendo

Tara Petersen

Project Director

Christina Doong

Quality Assurance Editor

David Allikas

Associate Editor

Jeanne Linke

Design Director

Charles Lebeda

Senior Designer

Leighanne Tillman

Designer

Jennifer Rittmann

Director of Sales

Andrew Colon

National Accounts Manager

Sara Stewart

National Accounts Representatives

Gabrielle Consola

John Quinn

National Accounts Associate, Digital Sales

Grace Kim

Corporate

Chairman/Chief Executive Officer

Mike Hennessy

Chief Financial Officer

Neil Glasser, CPA/CFE

Chief Operating Officer

Tighe Blazier

President, Managed Markets

Brian Haug

Vice President, Executive Creative Director

Jeff Brown

Executive Assistant

Teresa M. Fallon-Yandoli

Copyright © 2013 by Managed Care
& Healthcare Communications, LLC

Management of Patients With Homozygous Familial Hypercholesterolemia

Table of Contents

Participating Faculty

S250

Report

■ Management of Patients with Homozygous Familial Hypercholesterolemia

S251

Paul E. Ziajka, MD, PhD



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ AD119

Management of Patients With Homozygous Familial Hypercholesterolemia

This supplement was sponsored by **Aegerion Pharmaceuticals, Inc**, with editorial direction. Final content contained in this supplement was determined by the author and by the publishing staff of *The American Journal of Managed Care*.

• • •

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Management of Patients with Homozygous Familial Hypercholesterolemia

This supplement to *The American Journal of Managed Care* provides an overview of the pathophysiology, diagnosis and treatment of homozygous familial hypercholesterolemia (HoFH), presents data for 2 recently approved orphan drugs for HoFH, and discusses considerations for managed care regarding this rare disease.

■ Faculty

Paul E. Ziajka, PhD

Director
Florida Lipid Institute
Winter Park, Florida

■ Faculty Disclosures

Paul E. Ziajka, PhD, reports relationships with the following organizations:

Grants:

Genzyme

Honoraria:

Aegerion Pharmaceuticals, Inc
AstraZeneca
GlaxoSmithKline
Merck

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ SUPPLEMENT POLICY STATEMENT ■

Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

Publisher's Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.